Eris Lifesciences Limited Bombay S.E.

ERIS

INE406M01024

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 02:16:28 2024-04-25 am EDT			5-day change	1st Jan Change
881.1 ^INR	+1.22%		+1.25%	-3.24%

Apr. 03	Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	MT
Mar. 15	Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	MT

Tranche Update on Eris Lifesciences Limited's Equity Buyback Plan announced on July 3, 2019.

January 23, 2020 at 06:36 am EST

From July 3, 2019 to January 14, 2020, the company has repurchased 1,739,130 shares, representing 1.26% for INR 1,000 million. With this, the company has completed the repurchase of 1,739,130 shares, representing 1.26% for INR 1,000 million under the buyback announced on July 3, 2019.

Latest news about Eris Lifesciences Limited

Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	Apr. 02	MT
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	Mar. 15	MT
Transcript : Eris Lifesciences Limited - Shareholder/Analyst Call	Mar. 14
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	Mar. 14	MT
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	Mar. 14	RE
Eris Lifesciences Limited agreed to acquire Biocon Biologics India Branded Formulations business for INR 12.42 billion.	Mar. 13	CI
Eris Lifesciences Completes Purchase of 51% Stake in Swiss Parenterals	Feb. 15	MT
Eris Lifesciences Limited completed the acquisition of 51% stake in Swiss Parenterals Limited.	Feb. 14	CI
Eris Lifesciences Limited Provides Earnings Guidance for the Fiscal 2025 and Fiscal 2026	Feb. 13	CI
Transcript : Eris Lifesciences Limited, Q3 2024 Earnings Call, Feb 13, 2024	Feb. 13
Eris Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 13	CI
Eris Lifesciences Limited agreed to acquire 51% stake in Swiss Parenterals Limited INR 6.4 billion.	Feb. 12	CI
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns	Feb. 08	RE
Eris Lifesciences Limited completed the acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics	Nov. 09	CI
Indian shares set to open higher tracking Asian peers	Nov. 08	RE
Eris Lifesciences Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024	Nov. 08	CI
Transcript : Eris Lifesciences Limited, Q2 2024 Earnings Call, Nov 08, 2023	Nov. 08
Eris Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 08	CI
Eris Lifesciences Limited entered into a definitive agreement to acquire Dermatology and Nephrology branded formulations business units of Biocon Biologics for INR 3.7 billion.	Nov. 07	CI
Eris Lifesciences Limited Enters into Term Loan Agreement to Avail the Rupee Term Loan Facility from HDFC Bank Limited	23-09-29	CI
Transcript : Eris Lifesciences Limited, Q1 2024 Earnings Call, Aug 07, 2023	23-08-07
Eris Lifesciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-07	CI
Eris Lifesciences Gains Dermatology Trademarks Acquired from Glenmark via Deal with Unit Eris Oaknet	23-07-03	MT
Transcript : Eris Lifesciences Limited, Q4 2023 Earnings Call, May 17, 2023	23-05-17
Eris Lifesciences' Consolidated Profit Falls in Fiscal Q4	23-05-17	MT

Chart Eris Lifesciences Limited

Duration

Period

More charts

Company Profile

Eris Lifesciences Limited is an India-based company that is primarily engaged in the manufacturing and marketing of pharmaceutical products. The Companyâs manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals, and nutrients (VMN). The Company's brands include Advog 0.2, Atorsave Gold 10, Baga NT 100, Calshine 60K Tablet, Carpela, Cilentra Plus 5, Cognix, D1000cal, Enoxsave 60, Glimisave M 4 forte, Levroxa 1000, Mac Rabonik Plus, Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Companyâs wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited, and Eris Healthcare Private Limited.

Sector

Pharmaceuticals

Calendar

2024-05-22 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Eris Lifesciences Limited

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

870.1 INR

Average target price

1,081 INR

Spread / Average Target

+24.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.61%	660B
NOVO NORDISK A/S	+25.87%	562B
JOHNSON & JOHNSON	-5.24%	358B
MERCK & CO., INC.	+16.49%	322B
ABBVIE INC.	+8.28%	297B
ASTRAZENECA PLC	+7.09%	219B
ROCHE HOLDING AG	-9.12%	196B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals

Eris Lifesciences Limited Bombay S.E.

Equities

ERIS

INE406M01024

Pharmaceuticals

Tranche Update on Eris Lifesciences Limited's Equity Buyback Plan announced on July 3, 2019.

Latest news about Eris Lifesciences Limited

Chart Eris Lifesciences Limited

Company Profile

Income Statement Evolution

Ratings for Eris Lifesciences Limited

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals